Cargando…

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma

BACKGROUND: Molecular profiling allows tumor classification as well as assessment of diagnostic, prognostic, and treatment-related molecular changes. Translation into clinical practice and relevance for patients has not been demonstrated yet. METHODS: We analyzed clinical and molecular data of isoci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kessler, Tobias, Berberich, Anne, Casalini, Belen, Drüschler, Katharina, Ostermann, Hannah, Dormann, Andrea, Walter, Sandy, Hai, Ling, Schlesner, Matthias, Herold-Mende, Christel, Jungk, Christine, Unterberg, Andreas, Bendszus, Martin, Sahm, Katharina, von Deimling, Andreas, Winkler, Frank, Platten, Michael, Wick, Wolfgang, Sahm, Felix, Wick, Antje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212885/ https://www.ncbi.nlm.nih.gov/pubmed/32642725 http://dx.doi.org/10.1093/noajnl/vdz060

Ejemplares similares

Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis
por: Jungk, Christine, et al.
Publicado: (2016)

Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
por: Jungk, Christine, et al.
Publicado: (2019)

Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT
por: Jungwirth, Gerhard, et al.
Publicado: (2019)

DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma
por: Adeberg, Sebastian, et al.
Publicado: (2022)

Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma
por: Makarevic, Anastasia, et al.
Publicado: (2020)

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
por: Kickingereder, Philipp, et al.
Publicado: (2015)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes
por: Kessler, Tobias, et al.
Publicado: (2020)

Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas
por: Al-Ali, Ruslan, et al.
Publicado: (2019)

Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma
por: Jungk, Christine, et al.
Publicado: (2019)

Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease
por: Breckwoldt, Michael O., et al.
Publicado: (2019)

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone
por: Jungk, Christine, et al.
Publicado: (2016)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2015)

Emerging targets for anticancer vaccination: IDH
por: Platten, M., et al.
Publicado: (2021)

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
por: Wick, A., et al.
Publicado: (2022)

Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
por: Longuespée, Rémi, et al.
Publicado: (2018)

Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
por: Ott, Martina, et al.
Publicado: (2012)

K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017)

Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
por: Dao Trong, P., et al.
Publicado: (2023)

Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients
por: Jungk, Christine, et al.
Publicado: (2016)

Automatic Analysis of Cellularity in Glioblastoma and Correlation with ADC Using Trajectory Analysis and Automatic Nuclei Counting
por: Eidel, Oliver, et al.
Publicado: (2016)

Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
por: Dao Trong, Philip, et al.
Publicado: (2018)

Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?
por: Burth, Sina, et al.
Publicado: (2021)

Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma
por: Kaulen, Leon D, et al.
Publicado: (2022)

Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas
por: Blanco-Carmona, Enrique, et al.
Publicado: (2023)

Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy
por: Schnabel, Elena, et al.
Publicado: (2021)

Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score
por: Dao Trong, Philip, et al.
Publicado: (2023)

Oligosarcomas, IDH-mutant are distinct and aggressive
por: Suwala, Abigail K., et al.
Publicado: (2021)

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
por: Kessler, Tobias, et al.
Publicado: (2023)

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
por: Grassl, Niklas, et al.
Publicado: (2023)

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

Identification of KIF11 as a Novel Target in Meningioma
por: Jungwirth, Gerhard, et al.
Publicado: (2019)

The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
por: Schmoch, Thomas, et al.
Publicado: (2020)

Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
por: Seidel, Clemens, et al.
Publicado: (2011)

Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas
por: Dogan, Helin, et al.
Publicado: (2022)

Large-Scale Drug Screening in Patient-Derived IDH(mut) Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents
por: Dao Trong, Philip, et al.
Publicado: (2020)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology
por: Eidel, Oliver, et al.
Publicado: (2017)

Rapid-CNS(2): rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study
por: Patel, Areeba, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_10pctegp7sollah9rovp6hjatq